PMC:7205724 / 22340-22430
Annnotations
LitCovid-PubTator
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-PD-FMA-UBERON
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-PD-UBERON
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-PD-MONDO
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-PD-CLO
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sample-PD-NCBITaxon
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sample-sentences
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sample-PD-UBERON
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sample-Pubtator
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sample-Enju
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sample-PD-MAT
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sample-PD-FMA
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sample-PD-MONDO
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19
LitCovid-sentences
Rationale: Tocilizumab can treat lung injury in patients with critical and severe COVID-19